Starpharma Signs Drug Delivery License with AstraZeneca

Starpharma (OTC:

) today announced the signing of a licensing agreement with global pharmaceutical company AstraZeneca (NYSE:

). The agreement enables the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma's DEP® drug delivery technology. The DEP® platform centres on use of Starpharma's proprietary dendrimers, with the aim of enhancing the dosing and efficacy characteristics of pharmaceuticals. Under the agreement Starpharma is eligible to receive signature and milestone payments on one or more AstraZeneca DEP® products if they progress through the development pipeline, and milestone and royalty payments on any net sales of the resultant products. AstraZeneca will fund all development and commercialisation costs under the